These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36334121)

  • 21. A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients.
    Pamuk ÖN; Kalyoncu U; Aksu K; Omma A; Pehlivan Y; Çağatay Y; Küçükşahin O; Dönmez S; Çetin GY; Mercan R; Bayındır Ö; Çefle A; Yıldız F; Balkarlı A; Kılıç L; Çakır N; Kısacık B; Öksüz MF; Çobankara V; Onat AM; Sayarlıoğlu M; Öztürk MA; Pamuk GE; Akkoç N
    Rheumatol Int; 2016 Jul; 36(7):945-53. PubMed ID: 27221456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž; Tomšič M; Praprotnik S;
    Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gender Is a Risk Factor for Annual Decline in Estimated Glomerular Filtration Rate in Patients Treated with Biological DMARDs in Rheumatoid Arthritis and Ankylosing Spondylitis: a Retrospective Observational Study.
    Kim SK; Choe JY
    J Korean Med Sci; 2018 Jul; 33(30):e188. PubMed ID: 30034303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease activity after the discontinuation of biological therapy in inflammatory rheumatic diseases.
    Kádár G; Balázs E; Soós B; Laduver A; Keszthelyi P; Szekanecz Z; Kovács L
    Clin Rheumatol; 2014 Mar; 33(3):329-33. PubMed ID: 24497172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Shiba H; Son Y; Amuro H; Onishi A; Akashi K; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
    Arthritis Res Ther; 2020 Jun; 22(1):142. PubMed ID: 32539813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis and treatment of rheumatoid arthritis in the Emilia Romagna region: a prospective population-based study.
    Addimanda O; Marino M; Farina I; Trevisani M; Arrigoni E; Lumetti F; Crescentini F; Sambo P; Bezzi A; Bruschi M; Santilli D; Reta M; Bosi S; Delsante G; Girelli F; Montaguti L; Meliconi R; Sebastiani M; Ferri C; Malavolta N; Govoni M; Trombetti S; De Palma R; Salvarani C
    Clin Exp Rheumatol; 2017; 35(2):201-208. PubMed ID: 28134078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
    Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data.
    Kimyon G; Kalyoncu U; Kiraz S; Bes C; Coşkun N; Yağiz B; Küçükşahin O; Kanitez N; Erden A; Kiliç L; Bilgin E; Kaşifoğlu T; Emmungil H; Koca SS; Akar S; Çinar M; Yazisiz V; Ateş A; Ersözlü D; Gönüllü E; Mercan R; Ertenli İ
    Clin Exp Rheumatol; 2021; 39(4):852-858. PubMed ID: 32896266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis.
    Novella-Navarro M; Plasencia C; Tornero C; Navarro-Compán V; Cabrera-Alarcón JL; Peiteado-López D; Nuño L; Monjo-Henry I; Franco-Gómez K; Villalba A; Balsa A
    Arthritis Res Ther; 2020 Dec; 22(1):284. PubMed ID: 33298140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Failure and multiple failure for disease modifying antirheumatic drugs in rheumatoid arthritis: Real-life evidence from a tertiary referral center in Italy.
    Conigliaro P; D'Antonio A; D'Erme L; Lavinia Fonti G; Triggianese P; Bergamini A; Chimenti MS
    PLoS One; 2023; 18(2):e0281213. PubMed ID: 36730337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study.
    Lorenzin M; Ortolan A; Cozzi G; Calligaro A; Favaro M; Del Ross T; Doria A; Ramonda R
    Clin Rheumatol; 2021 Nov; 40(11):4569-4580. PubMed ID: 34136971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients.
    Ciechomska M; Bonek K; Merdas M; Zarecki P; Swierkot J; Gluszko P; Bogunia-Kubik K; Maslinski W
    Arch Immunol Ther Exp (Warsz); 2018 Oct; 66(5):389-397. PubMed ID: 29744553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in real-world settings.
    Ochiai M; Tanaka E; Sato E; Inoue E; Abe M; Saka K; Sugano E; Sugitani N; Higuchi Y; Yamaguchi R; Sugimoto N; Ikari K; Nakajima A; Yamanaka H; Harigai M
    Mod Rheumatol; 2021 Jul; 31(4):790-795. PubMed ID: 33538611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Necessity of TNF-alpha inhibitor discontinuation in rheumatoid arthritis is predicted by smoking and number of previously used biological DMARDs.
    Cuppen BV; Jacobs JW; Ter Borg EJ; Marijnissen AC; Bijlsma JW; Lafeber FP; van Laar JM;
    Clin Exp Rheumatol; 2017; 35(2):221-228. PubMed ID: 27749223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis.
    Codreanu C; Šírová K; Jarošová K; Batalov A
    Curr Med Res Opin; 2018 Oct; 34(10):1763-1769. PubMed ID: 29439591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry.
    Yoshida K; Kishimoto M; Radner H; Matsui K; Okada M; Saeki Y; Solomon DH; Tohma S
    Rheumatology (Oxford); 2016 Feb; 55(2):286-90. PubMed ID: 26350484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study.
    Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H
    PLoS One; 2019; 14(5):e0216624. PubMed ID: 31067271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
    Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
    Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry.
    Min HK; Kim HR; Lee SH; Shin K; Kim HA; Park SH; Kwok SK
    Clin Rheumatol; 2021 Aug; 40(8):3105-3113. PubMed ID: 33576925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world clinical experience of biological disease modifying anti-rheumatic drugs in Malaysia rheumatoid arthritis patients.
    Tan BE; Lim AL; Kan SL; Lim CH; Tsang EEL; Ch'ng SS; Mohd Noor N; Mohd Jamid N; Teh CL; Joshua Thundyil R; Loh YL; Chong HC; Ong SG; Mohamed Ismail A; Lee YYL; Gun SC
    Rheumatol Int; 2017 Oct; 37(10):1719-1725. PubMed ID: 28695274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.